A common medication already used for autoimmune diseases such as rheumatoid arthritis is effective for patients with giant ...

A common medication already used for autoimmune diseases such as rheumatoid arthritis is effective for patients with giant cell arteritis, according to findings from a team at the Perelman School of ...

The FDA has approved AbbVie’s RINVOQ (upadacitinib) for the treatment of giant cell arteritis, making it the ninth approved indication for the drug. This also marks the first time an oral JAK ...

GIANT CELL ARTERITIS: LINK WITH PMR, DIAGNOSIS & TREATMENT. Link with Polymyalgia Rheumatica (PMR)Giant Cell Arteritis (GCA), also known as Temporal Arteritis, often coexists with another ...

Typical histopathology of giant cell arteritis showing (A) transmural inflammatory infiltration with giant cell formation in the media, (B) intimal hyperplasia and (C) luminal occlusion. Comments ...

Giant cell arteritis (GCA) is a medical emergency. The concept of symptom-to-thrombolysis time in myocardial infarction and stroke is well established.

Giant cell arteritis (GCA), also known as temporal arteritis, is the most common systemic vasculitis in Western countries, primarily affecting adults aged over 50 years. 1,2 It is characterized by ...

Ever since the early use of cortisone for giant-cell arteritis in the 1950s,1 glucocorticoids have been a foundational treatment for this form of large-vessel vasculitis, providing clinical benefit ...

First systematic approach: The link between PMR and giant cell arteritis 35:14; 80 cases of PMR 38:13; Swedish autopsy studies 41:07; Introduction of advanced imaging in the 1990s 42:40; ...

Intracranial GCA appears to be more common than previously thought and is linked to higher rates of stroke and mortality.